Page 16 - Topline News Today

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) reported topline results from the phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the

Item 7.01. Regulation FD Disclosure. On June 7, 2022, Seres Therapeutics, Inc. posted a slide presentation on the topline data from the ECOSPOR IV open-label study of SER-109 in... | June 7, 2022

Montrouge, France, June 7, 2022 DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers 67.0% of subjects treated

THOUSAND OAKS (dpa-AFX) - Amgen, Inc. (AMGN) announced Tuesday positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult patients

Item 7.01. Regulation FD. On May 24, 2022, Motus GI Holdings, Inc. issued a press release announcing positive topline data from the European Union Feasibility Study of the Pure- Vu®... | May 24, 2022

- Data Accepted for Presentation at ESMO World Congress on Gastrointestinal Cancer - Seagen Inc. (Nasdaq:SGEN) today announced positive topline results from the pivotal phase 2 MOUNTAINEER clinical

WASHINGTON (dpa-AFX) - Biopharmaceutical company AbbVie Inc. (ABBV) announced on Wednesday positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult

Cystic Fibrosis Foundation  awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis Phase 2 expansion... | May 10, 2022

Detailed results to be presented at upcoming medical congress Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2, randomized, double-blinded, placebo-controlled trial of dazodalibep

Company Announcement Based on the topline results from the EPCORE NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next steps Data from the clinical